Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin + Atezolizumab vs Atezolizumab Maintenance in ES-SCLC
2023-503868-16-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of atezolizumab and lurbinectedin in small cell lung cancer (SCLC) (3 arms), sponsored by Roche. Primary endpoints: IRF-assessed progression-free survival (PFS) and Overall survival (OS). Planned start Feb 2022; status: authorised.
02
Drugs
atezolizumablurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2023-503868-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503868-16-00.